文献速递神经肿瘤功能神经外科

术前血清催乳素预测无功能垂体腺瘤术后内分泌结局:重新审视「柄效应」

Preoperative serum prolactin as a predictor of endocrine outcomes in nonfunctioning pituitary adenoma surgery: revisiting the "stalk effect".
PubMed 文献 · J Neurosurg · 2025-10-17

该单中心回顾性队列纳入244例接受内镜经鼻蝶手术的无功能垂体腺瘤患者,按术前催乳素是否高于参考上限分组。高催乳素组垂体柄偏移及术前继发性甲状腺功能减退、肾上腺功能不全更常见,术后新发继发性甲减和永久性肾上腺功能不全比例更高;术前高催乳素是术前继发性甲减及其术后恶化的独立预测因素。

要点

  • 无功能垂体腺瘤术前高催乳素者垂体柄偏移更常见,提示「柄效应」。
  • 术前高催乳素与术后新发继发性甲减及永久性肾上腺功能不全风险升高相关。
  • 术前催乳素可作为预测术后内分泌结局的生物标志物,辅助个体化围手术期管理。

核心结论

  • 无功能垂体腺瘤患者术前高催乳素与特定围手术期内分泌功能障碍风险升高及更明显的垂体柄偏移相关。
  • 术前催乳素水平可作为预测术后内分泌结局的生物标志物,有助于风险评估和个体化围手术期管理。

研究设计与样本

  • 单中心回顾性队列研究,纳入2013年1月至2023年4月接受内镜经鼻蝶手术治疗的无功能垂体腺瘤患者。
  • 共244例患者,男性140例(57%),中位年龄59岁,中位随访65个月;按术前催乳素是否高于性别校正参考上限分为正常组与高催乳素组。

主要发现

  • 244例中131例(54%)存在高催乳素血症。
  • 高催乳素组与正常组肿瘤大小相似(中位直径2.5 cm vs 2.3 cm,p=0.102),但海绵窦侵犯率(99% vs 91%,p=0.035)、垂体柄偏移(95% vs 74%,p=0.001)、垂体柄弯曲(14% vs 1%,p=0.001)更高。
  • 高催乳素组术前继发性甲状腺功能减退(39% vs 22%,p=0.005)和肾上腺功能不全(34% vs 22%,p=0.048)比例更高。
  • 术后高催乳素组新发继发性甲状腺功能减退(16% vs 7%,p=0.048)和新发永久性肾上腺功能不全(16% vs 6%,p=0.046)比例更高。
  • 多变量分析显示术前高催乳素是术前继发性甲状腺功能减退(OR 1.83,95%CI 1.17-3.44;p=0.046)及其术后恶化(OR 2.65,95%CI 1.02-7.69;p=0.042)的独立预测因素。

关键数值与推荐

  • 高催乳素血症定义为催乳素值高于性别校正的参考范围上限。
  • 术前高催乳素预测术前继发性甲状腺功能减退的OR为1.83(95%CI 1.17-3.44;p=0.046)。
  • 术前高催乳素预测术后继发性甲状腺功能减退恶化的OR为2.65(95%CI 1.02-7.69;p=0.042)。

临床怎么用

  • 对无功能垂体腺瘤患者术前应关注催乳素水平,高催乳素提示垂体柄受压及围手术期内分泌功能障碍风险升高。
  • 术前高催乳素患者应加强围手术期甲状腺和肾上腺功能评估与随访,以便早期发现和处理内分泌功能恶化。

局限性

  • 单中心回顾性设计可能引入选择偏倚和残余混杂。
  • 高催乳素组海绵窦侵犯率接近上限(99% vs 91%),提示两组肿瘤侵袭性存在差异,可能影响内分泌结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Nonfunctioning pituitary adenomas (NFPAs) often present with associated mild hyperprolactinemia, described in literature as "stalk effect." The presence of preoperative hyperprolactinemia caused by tumor compression of the pituitary stalk and endocrinological outcomes has been noted; however, a detailed investigation on the impact on perioperative endocrinological outcome is lacking. The authors aimed to determine whether elevated preoperative serum prolactin concentrations are associated with increased risk of perioperative pituitary dysfunction in patients with NFPAs undergoing endonasal transsphenoidal surgery (ETS). METHODS: The authors conducted a single-center retrospective cohort study of patients who underwent ETS for NFPAs between January 2013 and April 2023. Patients were divided into two groups based on preoperative prolactin concentrations: normal or hyperprolactinemic (prolactin values above upper limit of reference range, adjusted for sex). Outcomes included perioperative endocrinological function and surgical outcomes. Multivariable analysis was conducted to identify factors associated with perioperative endocrinological function outcomes. RESULTS: Of 244 patients (140 [57%] males; median age 59 years) with a median follow-up of 65 months, 131 (54%) had hyperprolactinemia. Compared with patients with normal preoperative prolactin levels (n = 113), the hyperprolactinemia group had similar tumor size (median diameter 2.5 cm vs 2.3 cm, p = 0.102) but higher rates of cavernous sinus invasion (99% vs 91%, p = 0.035), pituitary stalk deviation (95% vs 74%, p = 0.001), stalk bending (14% vs 1%, p = 0.001), preoperative secondary hypothyroidism (39% vs 22%, p = 0.005), and adrenal insufficiency (AI; 34% vs 22%, p = 0.048). Postoperatively, the hyperprolactinemia group showed higher rates of new secondary hypothyroidism (16% vs 7%, p = 0.048) and new permanent AI (16% vs 6%, p = 0.046). Multivariable analysis revealed preoperative high prolactin as an independent predictor of preoperative secondary hypothyroidism (OR 1.83, 95% CI 1.17-3.44; p = 0.046) and its postoperative deterioration (OR 2.65, 95% CI 1.02-7.69; p = 0.042). Maximum tumor diameter was also a significant predictor of various endocrinological dysfunctions both pre- and postoperatively. CONCLUSIONS: Preoperative hyperprolactinemia in patients with NFPA is associated with higher risks of specific perioperative endocrinological dysfunction and pronounced pituitary stalk deviation. These findings highlight the utility of preoperative prolactin levels as a biomarker for predicting postoperative endocrinological outcomes, potentially enhancing risk assessment and guiding personalized perioperative management.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shinya Y, Herndon JS, Palit SR, et al. Preoperative serum prolactin as a predictor of endocrine outcomes in nonfunctioning pituitary adenoma surgery: revisiting the "stalk effect". J Neurosurg. 2025. PMID: 41105988. doi:10.3171/2025.5.JNS243206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。